Close Menu

NEW YORK – Natera reported after the close of the market on Thursday that its fourth quarter 2020 revenues rose 35 percent year over year, driven by an increase in product revenue.

"Q4 2020 was the best quarter we've ever had at Natera," said CEO Steve Chapman during a conference call to discuss the financial results.

For the three months ended Dec. 31, 2020, Natera reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.